The impact of medications for opioid use disorder (MOUD) on retention and recovery capital in recovery housing: An exploratory causal inference analysis

Different MOUD agents were associated with distinct patterns in recovery outcomes. NTX was associated with higher predicted retention, while buprenorphine formulations promote early gains in recovery capital. These findings underscore the importance of aligning pharmacological strategies with individual recovery trajectories, particularly during the initial six months of residency. Further longitudinal research is needed to inform treatment-matching approaches based on motivational and clinical profiles.